Pulmatrix, Inc.

Pulmatrix, Inc.

Biotechnology • Healthcare • Framingham, MA, United States • PULM (NCM)

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

888 355 4440 945 Concord Street, Framingham, MA 01701, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets - PR Newswire
PR Newswire • Oct 16
Behavioral Patterns of PULM and Institutional Flows - Stock Traders Daily
Stock Traders Daily • Dec 26
Pulmatrix and its merger partner start scouting other deals amid delay - Stock Titan
Stock Titan • Dec 18
aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail - Pharmaceutical Technology
Pharmaceutical Technology • Sep 16
GNI Subsidiary Cullgen and Pulmatrix Relax Merger Terms to Seek Strategic Alternatives - The Globe and Mail
The Globe and Mail • Dec 20

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Pulmatrix, Inc. had layoffs?
No layoff events have been recorded for Pulmatrix, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Pulmatrix, Inc. have?
Pulmatrix, Inc. has approximately 2 employees.
What industry is Pulmatrix, Inc. in?
Pulmatrix, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Pulmatrix, Inc. a publicly traded company?
Yes, Pulmatrix, Inc. is publicly traded under the ticker symbol PULM on the NCM. The company has a market capitalization of approximately $0.01 billion.
Where is Pulmatrix, Inc. headquartered?
Pulmatrix, Inc. is headquartered in Framingham, MA, United States at 945 Concord Street, Framingham, MA 01701, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.